CIK 0001817229 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Vor Biopharma Inc.
Sign in to watch- Ticker
- VOR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 811591163
- Phone
- 617-655-6580
- Business address
- 500 BOYLSTON STREET, SUITE 1350, BOSTON, MA, 02116
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-15 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −53,644 | $16.01 | $859K | 3,197,619 |
| 2026-04-14 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −153,735 | $15.97 | $2.5M | 3,251,263 |
| 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −530,610 | $16.15 | $8.6M | 3,404,998 |
| 2026-04-10 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −828 | $15.75 | $13K | 3,935,608 |
| 2026-04-09 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −135,201 | $16.59 | $2.2M | 3,936,436 |
| 2026-04-08 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −353,242 | $16.32 | $5.8M | 4,202,499 |
| 2026-04-08 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −130,862 | $16.91 | $2.2M | 4,071,637 |
| 2026-04-06 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −537,754 | $16.51 | $8.9M | 4,607,244 |
| 2026-04-06 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −44,728 | $17.31 | $774K | 4,562,516 |
| 2026-04-06 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −6,775 | $18.50 | $125K | 4,555,741 |
| 2026-04-02 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −258,475 | $18.23 | $4.7M | 5,146,523 |
| 2026-04-02 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −1,525 | $19.06 | $29K | 5,144,998 |
| 2025-12-18 | Joustra Wouter Director | Grant or award · Stock Option (Right to Buy) | +3,000 | 3,000 | ||
| 2025-12-18 | Levin Andrew David Director | Grant or award · Stock Option (Right to Buy) | +3,000 | 3,000 | ||
| 2025-12-18 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award | −4,625,346 | $10.81 | $50.0M | 5,404,998 |
| 2025-12-18 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (Right to Buy) | +3,000 | 3,000 | ||
| 2025-12-05 | Zuraw Qing Che Chief Development Officer | Returned to the company · Employee Stock Option (right to buy) | −218,652 | 0 | ||
| 2025-12-05 | Zuraw Qing Che Chief Development Officer | Grant or award · Employee Stock Option (right to buy) | +218,652 | 218,652 | ||
| 2025-12-05 | Kress Jean-Paul CEO and Chairman | Returned to the company · Employee Stock Option (right to buy) | −4,164,831 | 0 | ||
| 2025-12-05 | Kress Jean-Paul CEO and Chairman | Grant or award · Employee Stock Option (right to buy) | +4,164,831 | 4,164,831 |
Page 2 of 18 · 344 trades